鞘内IgM合成是复发型多发性硬化疾病活动与严重程度的独立生物标志物
该研究纳入530例复发型多发性硬化患者,分析脑脊液IgG和IgM鞘内合成与炎症活动及慢性恶化指标的关系。结果显示,IgM鞘内合成(IgMIF)患者首次复发时间更短、MSSS更高、sNfL更高、T2w病灶更多,且这些关联在仅OCGB或OCGB/IgGIF阳性患者中缺失或较弱。
要点
- IgMIF患者中位首次复发时间缩短28个月,MSSS平均高1.11步。
- IgMIF≥中位者首次复发和启用高效治疗时间分别缩短32和203个月。
- IgMIF与MRI活动及sNfL呈剂量依赖关联,而IgGIF无此关联。
核心结论
- 鞘内IgM合成是复发型MS疾病活动性和严重程度的独立生物标志物。
研究设计与样本
- 研究纳入530例复发型MS患者,比较基线及随访时脑脊液、临床、MRI和sNfL数据。
- 患者按寡克隆IgG带及IgG和IgM鞘内合成情况分类,采用协变量校正统计模型分析。
主要发现
- IgMIF患者中位首次复发时间比无鞘内免疫球蛋白合成者缩短28个月,MSSS平均高1.11步。
- IgMIF患者sNfL浓度更高、新发/增大T2w病灶更多、总T2w病灶数更高(均p≤0.01)。
- 仅OCGB或OCGB/IgGIF阳性患者中上述关联缺失或较弱。
- IgMIF≥中位者首次复发和启用高效治疗时间分别比IgMIF<中位者缩短32和203个月(均p<0.01)。
- IgMIF与MRI疾病活动及sNfL呈剂量依赖关联,IgGIF无此关联。
关键数值与推荐
- IgMIF患者中位首次复发时间缩短28个月,MSSS平均高1.11步。
- IgMIF≥中位者首次复发时间缩短32个月,启用高效治疗时间缩短203个月(均p<0.01)。
- IgMIF患者sNfL更高、新发/增大T2w病灶更多、总T2w病灶数更高(均p≤0.01)。
临床怎么用
- 脑脊液IgM鞘内合成检测可用于识别疾病活动性和严重程度更高的复发型MS患者。
- IgMIF定量水平与MRI活动及sNfL呈剂量依赖关联,支持其作为独立生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to determine in relapsing multiple sclerosis (MS) whether intrathecal synthesis of immunoglobulin (Ig) M and IgG is associated with outcomes reflecting inflammatory activity and chronic worsening. METHODS: We compared cerebrospinal fluid analysis, clinical and magnetic resonance imaging data, and serum neurofilament light chain (sNfL) levels at baseline and follow-up in 530 patients with relapsing MS. Patients were categorized by the presence of oligoclonal IgG bands (OCGB) and intrathecal synthesis of IgG and IgM (intrathecal fraction [IF]: IgGIF and IgMIF ). Relationships with the time to first relapse, sNfL concentrations, T2-weighted (T2w) lesions, MS Severity Score (MSSS), and time to initiation of high-efficacy therapy were analyzed in covariate-adjusted statistical models. RESULTS: By categorical analysis, in patients with IgMIF the median time to first relapse was 28 months shorter and MSSS on average higher by 1.11 steps compared with patients without intrathecal immunoglobulin synthesis. Moreover, patients with IgMIF had higher sNfL concentrations, more new/enlarging T2w lesions, and higher total T2w lesion counts (all p ≤ 0.01). These associations were absent or equally smaller in patients who were positive for only OCGB or OCGB/IgGIF . Furthermore, quantitative analyses revealed that in patients with IgMIF ≥ median, the time to first relapse and to initiation of high-efficacy therapy was shorter by 32 and by 203 months, respectively (both p < 0.01), in comparison to patients with IgMIF < median. Dose-dependent associations were also found for IgMIF but not for IgGIF with magnetic resonance imaging-defined disease activity and sNfL. INTERPRETATION: This large study supports the value of intrathecal IgM synthesis as an independent biomarker of disease activity and severity in relapsing MS. ANN NEUROL 2021;90:477-489.
引用
- Oechtering J, Schaedelin S, Benkert P, et al. Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. Ann Neurol. 2021. PMID: 34057235. doi:10.1002/ana.26137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。